Aardvark Therapeutics’ IPO Lawsuit: A Cautionary Tale for Biotech VCs

The Lawsuit at a Glance

Investors in Aardvark Therapeutics, Inc. (NASDAQ: AARD) are suing the company over alleged misleading statements made between its February 2025 IPO and May 2026. The class-action lawsuit, filed by Bernstein Liebhard LLP, claims Aardvark artificially inflated its stock price, leading to significant losses for shareholders who purchased shares during or after the IPO (TMX Newsfile, 2026).

The case underscores a critical risk for venture capitalists and limited partners in biotech: pre-revenue companies with high burn rates and unproven science are inherently volatile, even when they go public. For founders, it serves as a reminder that transparency and realistic timelines are non-negotiable. For LPs, it’s a signal to scrutinize biotech investments with the same rigor as pre-IPO tech bets.

Why Biotech IPOs Are a Double-Edged Sword

Biotech IPOs have long been a high-stakes game for investors. Unlike software companies, which can scale with minimal capital, biotech firms often require years of R&D, regulatory approvals, and clinical trials before generating revenue. Aardvark’s IPO in February 2025 was positioned as a breakthrough in therapeutic innovation, but the lawsuit suggests the company may have overpromised its near-term prospects.

Key Risks for VCs and LPs

• Misaligned Timelines: Many biotech IPOs are priced based on projected milestones (e.g., FDA approvals) that may never materialize. Aardvark’s case shows how quickly investor sentiment can sour when those milestones are delayed or missed.

• Regulatory Scrutiny: The FDA’s bar for approval is notoriously high, and even promising candidates can face rejection. Aardvark’s alleged misleading statements could reflect pressure to meet investor expectations amid regulatory uncertainty.

• Liquidity Traps: Unlike tech IPOs, which often see immediate liquidity for early investors, biotech IPOs can trap capital in illiquid shares for years. If the science doesn’t pan out, LPs may find themselves holding worthless paper.

• Class-Action Liability: The lawsuit against Aardvark is just one of many in biotech. Founders and VCs must ensure their disclosures are airtight to avoid similar legal exposure.

What Founders Can Learn from Aardvark’s Mistakes

For founders in the biotech space, Aardvark’s lawsuit is a playbook of what not to do. The allegations suggest the company may have overstated its progress or downplayed risks to attract IPO investors. This is a critical misstep, particularly in a sector where trust is paramount.

Founder Takeaways

• Be Transparent About Timelines: Biotech investors understand that drug development is a marathon, not a sprint. Founders should avoid setting unrealistic expectations about approvals or revenue timelines.

• Prioritize Data Over Narrative: Aardvark’s alleged misleading statements likely stemmed from a desire to fit a compelling story to market conditions. Founders should let the data drive their pitch, not the other way around.

• Prepare for Regulatory Scrutiny: Even if a company’s science is sound, regulators may disagree. Founders should work closely with legal and compliance teams to ensure all disclosures are accurate and defensible.

• Build a Strong Board: Aardvark’s board may face scrutiny in the lawsuit. Founders should ensure their board includes independent directors with deep biotech expertise to provide unbiased oversight.

How LPs Should Evaluate Biotech Investments

For LPs, Aardvark’s case is a reminder to treat biotech investments with the same caution as pre-IPO tech bets. The sector’s high failure rate and long timelines demand a rigorous due diligence process.

LP Checklist for Biotech Investments

• Scientific Validation: Does the company’s science have peer-reviewed backing? Are there independent studies validating its approach?

• Regulatory Pathway: What’s the FDA’s stance on the company’s target indication? Are there precedents for similar drugs getting approved?

• Financial Runway: Does the company have enough cash to reach its next major milestone? What’s the burn rate, and how does it compare to peers?

• Management Track Record: Have the founders or executives successfully navigated drug development before? What’s their history with regulatory agencies?

• Legal and Compliance Risks: Are there pending lawsuits or regulatory investigations? How transparent is the company about its risks?

• Exit Strategy: Even if the science is sound, how will LPs realize returns? Are there clear acquisition targets or IPO pathways?

The Broader Implications for Biotech Investing

Aardvark’s lawsuit isn’t an isolated incident. The biotech sector has seen a wave of class-action lawsuits in recent years, often tied to IPOs or secondary offerings. These cases highlight a growing trend: investors are increasingly holding companies accountable for overpromising and underdelivering.

Industry Trends to Watch

• Increased Scrutiny of IPOs: The SEC and plaintiffs’ attorneys are paying closer attention to biotech IPOs, particularly those involving pre-revenue companies. Founders should expect more rigorous disclosure requirements.

• Shift Toward Later-Stage Investments: Some VCs are pulling back from early-stage biotech, opting instead for later-stage companies with de-risked assets. This could lead to a funding gap for early-stage innovators.

• Rise of Alternative Funding Models: With traditional IPOs riskier, some biotech firms are turning to alternative funding models, such as SPACs or strategic partnerships, to de-risk their capital needs.

• Focus on Real-World Evidence: Investors are increasingly demanding real-world data to validate a company’s claims. Founders should prioritize generating robust clinical and economic evidence.

What’s Next for Aardvark and Its Investors

The lawsuit against Aardvark is still in its early stages, but the implications are already clear. For investors, the case serves as a cautionary tale about the risks of investing in pre-revenue biotech companies. For founders, it’s a reminder that transparency and realistic expectations are critical to long-term success.

Timeline and Next Steps

• October 13, 2026: Deadline for investors to contact Bernstein Liebhard LLP to discuss their rights as part of the class-action lawsuit (TMX Newsfile, 2026).

• Discovery Phase: The lawsuit will likely enter the discovery phase, where both sides will gather evidence. This could take months or even years.

• Potential Settlements: Many class-action lawsuits in biotech end in settlements, particularly if the company’s disclosures are found to be materially misleading.

• Regulatory Fallout: Depending on the outcome, Aardvark may face additional scrutiny from the SEC or FDA, which could further impact its operations.

Bottom Line

Aardvark Therapeutics’ class-action lawsuit is a stark reminder that biotech investing is not for the faint of heart. For VCs and LPs, it underscores the need for rigorous due diligence, realistic expectations, and transparency. For founders, it’s a lesson in the importance of aligning narratives with data and preparing for the worst-case scenario.

Investors in pre-revenue biotech should treat Aardvark’s case as a case study in what can go wrong — and how to avoid it.